Research Topic · Peer-Reviewed

Bt474 Cells

BT474 cells are a human breast cancer cell line that overexpresses the HER2 (ERBB2) receptor and are widely used as an in vitro model for studying HER2-positive breast cancer and its response to targeted therapies. Because HER2 amplification drives an aggressive subset of breast cancers, BT474 and related HER2-overe…

Curated from this journal's research 📚 1 peer-reviewed article cited Cited 3× across the literature 🔖 ISSN 2372-6601 🗓 Reviewed July 2026

Overview

BT474 cells are a human breast cancer cell line that overexpresses the HER2 (ERBB2) receptor and are widely used as an in vitro model for studying HER2-positive breast cancer and its response to targeted therapies. Because HER2 amplification drives an aggressive subset of breast cancers, BT474 and related HER2-overexpressing lines provide a controlled system for investigating tumor cell biology, signaling pathways, and the mechanisms of drugs such as the tyrosine kinase inhibitor lapatinib. Researchers use these cells to characterize how treatment alters the cellular proteome, identifying proteins whose abundance changes in response to inhibition and that may serve as markers of drug response or candidates for new treatment strategies. Reproducible, quantitative approaches such as ion-current-based LC-MS proteomics allow thousands of proteins to be measured and significant treatment-induced changes to be detected. BT474 cells frequently appear alongside other breast cancer lines such as SKBR3 and HCC1954 in comparative studies. Related open-access research using BT474 and similar HER2-positive cell lines in cancer proteomics is available.

Research published in this journal

1 peer-reviewed article, ranked by relevance. Each links to its DOI.

How this research is being cited

The 1 article above has been cited 3 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Bt474 Cells, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Jayadev Manikkam Umakanthan · United States Shuaiying Cui · United States Benedetto Sacchetti · Italy

This page summarises published research for orientation; it is not medical or professional advice.